16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.
15 September 2026
11 September 2026
10 September 2026
10 September 2026
More News
10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.
9 September 2026 The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent.
8 September 2026 With technical specialisms including nucleic acid technologies, biological therapeutics and vaccines, and diagnostics and biological assays, the new hire adds a life sciences patent specialism to the firm’s growing IP practice.
7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.
4 September 2026 Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.
4 September 2026 Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies.
3 September 2026 A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.
Latest Features
Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Pharma
Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.
MedTech
A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Europe
Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Europe
After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.
Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Latest Events Videos
Americas
Integrating AI into patent workflows promises efficiency gains, but requires strict oversight regarding accuracy, ethics, and data security. This panel explores the practical realities of deploying AI tools responsibly while maintaining the high standards required in life sciences prosecution.
Americas
Is Brazil moving toward a more predictable patent system, or simply shifting risk? This session examines the far-reaching impact of the ADI 5529 ruling, analysing how the end of automatic patent term extensions is reshaping filing and enforcement strategies.
Regulation & Industry
The post-grant challenge landscape is intensifying on both sides of the Atlantic. This panel analyses recent developments in IPRs, PGRs, EPO oppositions, and the UPC, detailing strategies to simultaneously defend existing portfolios and clear competitive space.
Americas
Choosing between patent protection and trade secrets is a delicate balancing act, especially amid regulatory scrutiny and unpredictable patent office timelines. This session delves into the frontlines of IP strategy, offering practical guidance on when each protection mechanism serves best.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox